RT
Madrigal Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Resmetirom (Rezdiffra™) | MASH with moderate to advanced fibrosis (F2-F3) | Approved |
| Resmetirom | MASH with compensated cirrhosis (F4) | Phase 3 |
Leadership Team at Madrigal Pharmaceuticals
BS
Bill Sibold
Chief Executive Officer and Director
DS
David Soergel, M.D.
Executive Vice President, Chief Medical Officer